Emcure Pharmaceuticals Limited — Irinotecan Exporter Profile
Indian Pharmaceutical Exporter · #13 for Irinotecan · $155.4K export value · DGFT Verified
Emcure Pharmaceuticals Limited is the #13 Indian exporter of Irinotecan with $155.4K in export value and 10 verified shipments. Emcure Pharmaceuticals Limited holds a 0.4% market share in Irinotecan exports across 2 countries. The company exports 39 pharmaceutical products worth $147.8M across 19 therapeutic categories.
Emcure Pharmaceuticals Limited — Irinotecan Export Profile: Buyers & Destinations
Where Does Emcure Pharmaceuticals Limited Export Irinotecan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SAUDI ARABIA | $93.8K | 5 | 68.6% |
| MOROCCO | $42.9K | 5 | 31.4% |
Emcure Pharmaceuticals Limited exports Irinotecan to 2 countries. The largest destination is SAUDI ARABIA accounting for 68.6% of Emcure Pharmaceuticals Limited's Irinotecan shipments. These destinations reflect Emcure Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Irinotecan from Emcure Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ARABIAN HEALTH CARE SUPPLY CO. | SAUDI ARABIA | $59.4K | 3 |
| GENERATION SANTE | MOROCCO | $42.9K | 5 |
| ARABIAN HEALTH CARE SUPPLY CO | SAUDI ARABIA | $34.4K | 2 |
Emcure Pharmaceuticals Limited supplies Irinotecan to 3 buyers globally. The largest buyer is ARABIAN HEALTH CARE SUPPLY CO. (SAUDI ARABIA), followed by GENERATION SANTE (MOROCCO) and ARABIAN HEALTH CARE SUPPLY CO (SAUDI ARABIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Irinotecan Export Value and How Much Does Emcure Pharmaceuticals Limited Contribute?
India exported $37.5M worth of Irinotecan through 2,905 shipments from 164 suppliers to 111 countries, serving 495 buyers globally. Emcure Pharmaceuticals Limited contributes $155.4K to this total, accounting for 0.4% of India's Irinotecan exports. Emcure Pharmaceuticals Limited ships Irinotecan to 2 countries through 3 buyers.
What Is the Average Shipment Value for Emcure Pharmaceuticals Limited's Irinotecan Exports?
Emcure Pharmaceuticals Limited's average Irinotecan shipment value is $15.5K per consignment, based on 10 shipments totaling $155.4K. The largest destination is SAUDI ARABIA (68.6% of Emcure Pharmaceuticals Limited's Irinotecan exports).
How Does Emcure Pharmaceuticals Limited Compare to Other Indian Irinotecan Exporters?
Emcure Pharmaceuticals Limited ranks #13 among 164 Indian Irinotecan exporters with a 0.4% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($14.7M), FRESENIUS KABI ONCOLOGY LIMITED ($10.4M), EUGIA PHARMA SPECIALITIES LIMITED ($4.4M). Emcure Pharmaceuticals Limited processed 10 shipments to 2 destination countries.
What Irinotecan Formulations Does Emcure Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA: IMTUS 100 MG INJECTION (IRINOTECAN HYDROCHLORIDE INJECTION 100MG/5ML)-1VIAL(INV.NO.: 2402300696 DT. 07.02.2024)VLS | $50.0K | 1 |
| IMTUS 100 MG INJ 1 VIAL IRINOTECAN HYDROCHLORIDE INJECTION 100MG 5ML B NO ELA1AH5001 MFG 01 05 2025 EXP 30 04 2027 | $34.4K | 1 |
| PHARMA: IMTUS 100 MG INJECTION (IRINOTECAN HYDROCHLORIDE INJECTION 100MG/5ML)-1VIAL(INV.NO.: 2402300694 DT. 07.02.2024)VLS | $26.0K | 1 |
| PHARMACEUTICALS PRODUCTS( FINISHED PRODUCT)-IMTUS 100 MG INJ 1 VIAL( IRINOTECANHYDROCHLORIDE INJECTION 100MG/5ML ) | $9.4K | 2 |
| PHARMA: IMTUS 100 MG INJECTION (IRINOTECAN HYDROCHLORIDE INJECTION 100MG/5ML)-1VIAL(INV.NO.: 2402300722 DT. 20.02.2024) | $6.2K | 1 |
| PHARMA SAMPLE HAVING N.C.V.:IMTUS 100MGINJECTION(IRINOTECAN HYDROCHLORIDE INJ.100MG/5ML)-1VIAL(I.NO.2402300723/20.2.24) | $6.1K | 1 |
| PHARMA IMTUS 100 MG INJECTION IRINOTECAN HYDROCHLORIDE INJECTION 100MG 5ML 1VIAL INV NO 2303100458 DT 08 03 2023 | $4.6K | 1 |
| PHARMA SAMPLE HAVING N C V IMTUS 100MGINJECTION IRINOTECAN HYDROCHLORIDE 100MG 5ML 1 VIAL I NO 2303100459 8 03 23 | $49 | 1 |
| IMTUS 100 MG INJ 1 VIAL IRINOTECAN HYDROCHLORIDE INJECTION 100MG 5ML B NO ELA1AH5001 MFG 01 05 2025 EXP 30 04 2027 FOC | $1 | 1 |
Emcure Pharmaceuticals Limited exports 9 distinct Irinotecan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA: IMTUS 100 MG INJECTION (IRINOTECAN HYDROCHLORIDE INJ with 1 shipments worth $50.0K.
How Does Emcure Pharmaceuticals Limited Compare to Nearest Irinotecan Exporters?
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | GLAND PHARMA LIMITED | $200.0K | 4 | 1 | $50.0K |
| 12 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $165.1K | 18 | 3 | $9.2K |
| 13 | EMCURE PHARMACEUTICALS LIMITED ★ | $155.4K | 10 | 2 | $15.5K |
| 14 | THERDOSE PHARMA PRIVATE LIMITED | $143.3K | 21 | 6 | $6.8K |
Emcure Pharmaceuticals Limited ranks #13 among 164 Indian Irinotecan exporters. Average shipment value of $15.5K compared to the market average of $228.7K. The closest competitors by value are GLAND PHARMA LIMITED and NAPROD LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Irinotecan Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 300 | 10.3% |
| SAHAR AIR | 296 | 10.2% |
| AHEMDABAD AIR ACC (INAMD4) | 252 | 8.7% |
| MUNDRA SEA (INMUN1) | 217 | 7.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 207 | 7.1% |
| DELHI AIR | 205 | 7.1% |
| AHEMDABAD AIR | 205 | 7.1% |
| MUNDRA SEA | 152 | 5.2% |
Geopolitical & Trade Policy Impact on Emcure Pharmaceuticals Limited's Irinotecan Exports
Emcure's extensive export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic adjustments in logistics and supply chain management to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have opened opportunities for Indian pharmaceutical companies like Emcure to expand their footprint in the US market. The US's inclination to diversify its supply chain away from China presents a favorable environment for Indian exporters to increase their market share.
In the European Union, stringent regulatory changes, such as the Falsified Medicines Directive, impose additional compliance requirements on exporters. Emcure's adherence to these regulations is crucial for maintaining and expanding its presence in the EU market.
Emcure Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Emcure's export operations. The company has consistently met the Good Manufacturing Practice (GMP) requirements set by the FDA, WHO, and EU authorities. However, the evolving regulatory landscape demands continuous investment in quality assurance and compliance mechanisms to ensure uninterrupted market access.
Recent incidents, such as the brief shutdown of the Pune plant due to a fire, highlight the importance of robust risk management and compliance strategies to maintain operational continuity and regulatory adherence. (tipranks.com)
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited exports 39 products worth $147.8M. Beyond Irinotecan, top products include Dolutegravir, Mycophenolate, Tenofovir, Iron, Melphalan. View the complete Emcure Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Irinotecan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Irinotecan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Emcure Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 10 individual customs records matching Emcure Pharmaceuticals Limited exporting Irinotecan, covering 9 formulations to 2 countries via 3 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 111+ countries, 495+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Irinotecan Export Data from Emcure Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Emcure Pharmaceuticals Limited's Irinotecan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Emcure Pharmaceuticals Limited
Full Company Profile →
39 products · $147.8M total trade · 19 categories
Irinotecan Stats
Company Overview
Top Products by Emcure Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Emcure Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Irinotecan. For current shipment-level data, contact TransData Nexus.